Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
5 hedge funds and large institutions have $29K invested in Lixte Biotechnology Warrants in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0.55% more ownership
Funds ownership: 1.17% → 1.72% (+0.55%)
12% less capital invested
Capital invested by funds: $33K → $29K (-$4K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$17.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$4.28K |
| 2 |
EAM
Empery Asset Management
New York
|
-$1.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$216 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Empery Asset Management
New York
| $12K | -$1.1K | -5,428 | -5% |
|
|
CS
2
Clear Street
New York
| $10K | +$17.2K | +85,211 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4K | +$3.77K | +18,674 | +137% |
|
|
WAM
4
Warberg Asset Management
Winnetka,
Illinois
| $2K | -$4.28K | -21,203 | -64% |
|
|
5
UBS Group
Zurich,
Switzerland
| $1K | -$216 | -1,067 | -12% |
|
LIXTW Hedge Fund Activity: Q2 2022 in Review
5 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q2 2022, worth a combined $29K — down 12% from $33K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new LIXTW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $17.2K. The largest seller was Warberg Asset Management, cutting an estimated $4.28K.
- 5 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q2 2022, up from 4 in Q1 2022.
- Funds reported $29K of Lixte Biotechnology Warrants stock for Q2 2022, down 12% quarter-over-quarter.
- 1 fund opened new Lixte Biotechnology Warrants positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q2 2022 was Clear Street, an estimated $17.2K added.
- The largest Lixte Biotechnology Warrants seller in Q2 2022 was Warberg Asset Management, an estimated $4.28K sold.
Based on aggregated 13F filings for Q2 2022.